STAT+: Greece’s antitrust regulator probes Novartis over practices tied to a pricey eye drug
STAT
SEPTEMBER 3, 2024
These practices, which occurred between 2009 and 2017, allegedly harmed the country and patients. At the same time, the agency is examining accusations that the drug company disseminated “defamatory claims and news” in hopes of influencing physicians and consumers to favor its own treatment over competing medicines.
Let's personalize your content